Q-linea
its ASTar system runs rapid phenotypic antibiotic susceptibility testing directly from positive blood culture, and the company recently announced FDA clearance of an expanded ASTar blood-testing menu, extending the platform's antibiotic and pathogen coverage.
- Country
- Sweden
Growth
ASTar system
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Rapid antibiotic-resistance tests | diagnostics-medtech | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.